Jupiter Asset Management Ltd. Raises Stock Holdings in DexCom, Inc. $DXCM

Jupiter Asset Management Ltd. boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 254.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 183,265 shares of the medical device company’s stock after purchasing an additional 131,604 shares during the period. Jupiter Asset Management Ltd.’s holdings in DexCom were worth $12,163,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Brighton Jones LLC raised its holdings in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares during the period. Integrated Wealth Concepts LLC boosted its holdings in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares during the period. Empowered Funds LLC increased its stake in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth lifted its position in shares of DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after purchasing an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after purchasing an additional 258 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the sale, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,871 shares of company stock valued at $2,306,638 over the last three months. 0.28% of the stock is owned by corporate insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $73.74 on Friday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a market capitalization of $28.45 billion, a PE ratio of 31.51, a price-to-earnings-growth ratio of 1.20 and a beta of 1.40. The business’s fifty day moving average price is $64.17 and its 200 day moving average price is $66.44.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.32 EPS. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Benchmark started coverage on shares of DexCom in a research note on Monday, May 11th. They set a “buy” rating and a $77.00 target price on the stock. Sanford C. Bernstein set a $77.00 price objective on DexCom in a research report on Friday, May 1st. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Canaccord Genuity Group set a $82.00 target price on DexCom and gave the company a “buy” rating in a report on Monday, May 18th. Finally, Robert W. Baird set a $80.00 price objective on DexCom in a research note on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.42.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.